B01AC07 - Dipyridamole |
Not porphyrinogenic |
NP |
Rationale
No CYP-interactions. Three references consider it safe.
Chemical description
Platelet inhibitor administered as tablets in a dose of 200 mg, Maximal plasma levl is 2.6 ug/mL. In main parts excreted unmetabolized in faeces. Metabolism takes place by conjugation with glucuronic acid. South African list: Use. French list: Authorized. Michael Moore’s list: safe. C.Andersson; patient reports: tolerated (n=1)
IPNet drug reports
Uneventful use reported in 1 patients with acute porphyria.
Similar drugs
References
Tradenames
Dipyridamol · Persantin 
Persantin 
Attia · Dipyridamole · Ofcram PR · Persantin · Persantin Retard · Pyridantin · Trolactin 
Dipyridamol · Persantin · Pyranistole 
Aponova · Dipyridamol · Persantin 
Dipyridamole · Persantine 
Persantin 
Persantin 
Dipiridamol · Persantin 
Attia · Cerebrovase · Dipyridamole · Iv persantine · Modaplate · Ofcram · Persantin · Persantine · Pyridantin · Vasyrol 
Dipiridamol 
Dipyridamole